30 results about "Claudin Proteins" patented technology

Provided herein are anti-CLDN antibodies and antibody drug conjugates (ADC), including derivatives thereof, and methods of using the same to treat proliferative disorders.

The present invention provides a combination therapy for effectively treating and / or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.

A method of tightening inter-cellular junctions in retinal or choroidal vessel cells includes exposing the retinal or choroidal vessel cells to norrin. Upon sufficient contact time, for norrin to selectively up-regulate gene expression of VE-cadherin or claudin-5 in the retinal or choroidal vessel cells, the inter-cellular junctions are tightened. The method is also suitable for treating retinal pigment epithelial cells in wet macular degeneration.

The present invention relates to antibodies against claudin 18.2 for use in cancer diagnosis. The present invention relates to antibodies directed against epitopes located in the C-terminal part of CLDN18.2, which are useful, for example, in diagnosing cancer and / or determining whether cancer cells express CLDN18.2.

The present invention relates to antibodies against claudin 18.2 for use in cancer diagnosis. The present invention relates to antibodies directed against epitopes located in the C-terminal portion of CLDN18.2, which are useful, for example, in diagnosing cancer and / or determining whether cancer cells express CLDN18.2.

Vascular disruption induced by interactions between tumor-secreted permeability factors and adhesion proteins on endothelial cells promotes metastasis The role of tumor-secreted angiopoietin-like 4 (cANGPTL4) in vascular leakage and metastasis is controversial due to a lack of understanding of how cANGPTL4 regulates vascular integrity. Here, we show that cANGPTL4 contributes to disruption of endothelial continuity and thus metastasis by directly interacting with 3 novel binding partners integrin α5β1, VE-cadherin and claudin‑5 in a temporally sequential manner. We show that cANGPTL4 binds to and activates integrin α5β1-mediated Rac1 / PAK signaling to attenuate cell–cell contacts. cANGPTL4 subsequently associates with and dissociates VE‑cadherin and claudin‑5, leading to endothelial disruption. Interfering with the formation of these cANGPTL4 complexes delays vascular destruction. In vivo vascular permeability and metastasis assays using ANGPTL4-knockout and wild-type mice injected with control or ANGPTL4-knockdown tumors confirmed that cANGPTL4 induces vascular leakiness and promotes lung metastasis in mice. Thus, our findings explain how cANGPTL4 induces endothelial disruption. Our findings have immediate implications for targeting cANGPTL4 to treat cancer and other vascular lesions.

The present invention is a prognostic diagnostic marker Claudin21 for ovarian cancer and its application. For the first time, it is found that the expression level of the ovarian cancer drug resistance marker Claudin21 is related to the prognosis of ovarian cancer, specifically the progression-free survival and overall survival when Claudin21 is highly expressed. Among the medium prognostic indicators, ovarian cancer cases show poor prognosis, that is, the discovery of the present invention provides prognosis hints for clinical treatment of ovarian cancer including chemotherapy and surgical treatment.

The present invention provides a combination therapy for effectively treating and / or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.

The present invention relates to a humanized antibody that binds to claudin 18.2 and is used for treating cancer. The antibody does not bind to Claudin18.1, but selectively binds to Claudin18.2, destroys the tight junction between cells, and makes Claudin18. 2 can not play its normal function, can be used for the prevention or treatment of tumors, especially advanced gastric cancer.

The invention provides a microsphere turner. The device includes a holder, a positioning table, a flip handle, a dynamic sealing structure, a sealing cover, and a negative pressure interface. The dynamic sealing structure includes a fixed cavity, a sealing ring and a rotating shaft; the holder is connected to one end of the rotating shaft, and the sealing The cover is connected to the other end of the rotating shaft; the turning handle is fixedly connected to the rotating shaft, and the positioning platform is closely connected to the turning handle; the fixed cavity is connected to the rotating shaft, and the rotating shaft is provided with annular grooves and air holes for forming a stable vacuum degree; The pressure port is fixedly connected with the fixed cavity. The microsphere flipper of the present invention is simple to operate, has mild conditions and is easy to control, and is suitable for 180° flipping and docking of microspheres in the preparation process of polyvinyl alcohol coating.